{
    "clinical_study": {
        "@rank": "28453", 
        "acronym": "in vivoTICE", 
        "arm_group": {
            "arm_group_label": "Trans-intestinal cholesterol excretion in vivo", 
            "arm_group_type": "Other", 
            "description": "Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients"
        }, 
        "brief_summary": {
            "textblock": "So far, the liver has been the main target for cholesterol elimination. However, several\n      recent studies performed in mice have described a new route of cholesterol excretion, the\n      Trans-Intestinal Cholesterol Excretion or TICE. TICE allows direct elimination of plasma\n      cholesterol in the feces directly via the intestine. Until now, only indirect evidence\n      suggests that TICE is also active in humans, the goal of this proof of concept study is to\n      provide the first proof of its existence in humans by using stable isotopes in patients with\n      bile duct diversion."
        }, 
        "brief_title": "in Vivo TICE (TransIntestinal Cholesterol Excretion)", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Occlusion of Bile Duct With an External Bile Diversion.", 
        "condition_browse": {
            "mesh_term": "Cholestasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - External bile duct diverted patients\n\n        Exclusion Criteria:\n\n          -  Inflammatory bowel disease\n\n          -  Aphagia\n\n          -  Renal or hepatocellular insufficiency\n\n          -  Primary intestinal tumor\n\n          -  Cholangitis or severe sepsis\n\n          -  Acute or chronic diarrhea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958216", 
            "org_study_id": "RC11_0008"
        }, 
        "intervention": {
            "arm_group_label": "Trans-intestinal cholesterol excretion in vivo", 
            "description": "At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.", 
            "intervention_name": "Intravenous injection of deuterated cholesterol diluted in intralipid 20%", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "TICE-human-stable isotopes", 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "contact": {
                "email": "bertrand.cariou@univ-nantes.fr", 
                "last_name": "Bertrand Cariou, Professor", 
                "phone": "+33 (0)2 53 48 27 07"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44000"
                }, 
                "name": "University Hospital"
            }, 
            "investigator": {
                "last_name": "Bertrand Cariou, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "In Vivo TICE (TransIntestinal Cholesterol Excretion) Measurement in Bile Duct Diverted Patients", 
        "overall_contact": {
            "email": "bertrand.cariou@univ-nantes.fr", 
            "last_name": "Bertrand CARIOU, Professor", 
            "phone": "+33 (0)2 53 48 27 07"
        }, 
        "overall_contact_backup": {
            "email": "Cedric.Lemay@univ-nantes.fr", 
            "last_name": "Cedric LE MAY, Doctor", 
            "phone": "+33 (0)2 28 08 01 66"
        }, 
        "overall_official": {
            "affiliation": "Nantes University Hospital", 
            "last_name": "Bertrand Cariou, Pofessor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients", 
            "measure": "Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients", 
            "safety_issue": "No", 
            "time_frame": "Day 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}